• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较(二维与三维)培养体系和培养基对患者来源的和标准的非小细胞肺癌细胞株对 EGFR 抑制剂的靶基因表达和反应的影响。

Format (2D vs 3D) and media effect target expression and response of patient-derived and standard NSCLC lines to EGFR inhibitors.

机构信息

DCTD National Cancer Institute, Bethesda, MD, United States.

DCTD National Cancer Institute, Bethesda, MD, United States.

出版信息

Cancer Treat Res Commun. 2021;29:100463. doi: 10.1016/j.ctarc.2021.100463. Epub 2021 Sep 25.

DOI:10.1016/j.ctarc.2021.100463
PMID:34601320
Abstract

Three patient-derived NSCLC lines and three well-established NSCLC lines with varied EGFR gene status were compared for expression of EGFR protein, proliferation and epithelial and mesenchymal markers in monolayer, simple spheroid and complex spheroid cultures. The effects of diverse culture conditions and exposure time on the response of the six NSCLC lines to the EGFR inhibitors erlotinib, afatinib, lapatinib, and osimertinib were examined. The clinical Cmax was used as the test concentration to determine whether cells were responsive or resistant to each agent. Among the patient-derived lines, LG0703-F948, which has an EGFR L858R mutation, was responsive to each of the four EGFR inhibitor when grown as spheroids but resistant when grown in monolayer. The HCC827 line, which carries an EGFR E746-A750 deletion, was responsive to each of the four EGFR inhibitors when grown as spheroids or monolayers. NCI-H1975 cells which have an EGFR T790M mutation and an EGFR L858R mutation, were sensitive to osimertinib when propagated as spheroids but not when grown in monolayer. The results suggest that the expression of cell surface targets and response to drugs targeting cell surface proteins varies depending upon cell culture format. These findings may help to explain, in part, the concordance or discordance between cell culture and in vivo findings in experimental systems.

摘要

比较了三种患者来源的 NSCLC 细胞系和三种具有不同 EGFR 基因状态的成熟 NSCLC 细胞系,以评估其在单层、简单球体和复杂球体培养物中 EGFR 蛋白表达、增殖以及上皮和间充质标志物的表达情况。还研究了不同培养条件和暴露时间对六种 NSCLC 细胞系对 EGFR 抑制剂厄洛替尼、阿法替尼、拉帕替尼和奥希替尼反应的影响。临床 Cmax 被用作测试浓度,以确定细胞对每种药物的反应是敏感还是耐药。在患者来源的细胞系中,携带 EGFR L858R 突变的 LG0703-F948 在作为球体生长时对四种 EGFR 抑制剂中的每一种均有反应,但在作为单层生长时则耐药。携带 EGFR E746-A750 缺失的 HCC827 细胞系在作为球体或单层生长时对四种 EGFR 抑制剂均有反应。具有 EGFR T790M 突变和 EGFR L858R 突变的 NCI-H1975 细胞在作为球体生长时对奥希替尼敏感,但在作为单层生长时则不敏感。结果表明,细胞表面靶标的表达和对细胞表面蛋白靶向药物的反应取决于细胞培养方式。这些发现可能部分有助于解释实验系统中细胞培养和体内研究结果的一致性或不一致性。

相似文献

1
Format (2D vs 3D) and media effect target expression and response of patient-derived and standard NSCLC lines to EGFR inhibitors.比较(二维与三维)培养体系和培养基对患者来源的和标准的非小细胞肺癌细胞株对 EGFR 抑制剂的靶基因表达和反应的影响。
Cancer Treat Res Commun. 2021;29:100463. doi: 10.1016/j.ctarc.2021.100463. Epub 2021 Sep 25.
2
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.针对非小细胞肺癌细胞中的表皮生长因子受体:RNA 干扰与酪氨酸激酶抑制剂或西妥昔单抗联合的效果。
BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.
3
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.HM781-36B 在耐厄洛替尼的 NSCLC 及其他 EGFR 依赖型癌症模型中作为一种高效的泛 HER 抑制剂的抗肿瘤活性。
Int J Cancer. 2012 May 15;130(10):2445-54. doi: 10.1002/ijc.26276. Epub 2011 Aug 24.
4
Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation.单层培养通过取消 microRNA 介导的反馈调节改变 EGFR 抑制剂的反应。
Sci Rep. 2024 Mar 27;14(1):7303. doi: 10.1038/s41598-024-56920-7.
5
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.阿帕替尼增强了表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)对具有EGFR-TKI耐药性的非小细胞肺癌的抗肿瘤活性。
Eur J Cancer. 2017 Oct;84:184-192. doi: 10.1016/j.ejca.2017.07.037. Epub 2017 Aug 17.
6
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.持续表皮生长因子受体(EGFR)抑制的疗效以及刺猬信号通路(Hedgehog)在具有EGFR激活突变的人肺癌细胞EGFR获得性耐药中的作用
Oncotarget. 2017 Apr 4;8(14):23020-23032. doi: 10.18632/oncotarget.15479.
7
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.抑制Polo样激酶1可降低携带T790M突变的非小细胞肺癌对表皮生长因子受体抑制的获得性耐药。
Oncotarget. 2016 Jul 26;7(30):47998-48010. doi: 10.18632/oncotarget.10332.
8
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.非小细胞肺癌中不耐药的罕见 EGFR 突变:突变模式、表皮生长因子受体酪氨酸激酶抑制剂的有效性和预后因素。
Eur J Cancer. 2019 Sep;119:77-86. doi: 10.1016/j.ejca.2019.06.025. Epub 2019 Aug 16.
9
Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development.三维肺肿瘤微环境在体外调节治疗性化合物反应性——对药物开发的启示
PLoS One. 2014 Mar 17;9(3):e92248. doi: 10.1371/journal.pone.0092248. eCollection 2014.
10
Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.表皮生长因子受体突变型非小细胞肺癌中厄洛替尼诱导的自噬。
Lung Cancer. 2013 Sep;81(3):354-361. doi: 10.1016/j.lungcan.2013.05.012. Epub 2013 Jun 13.

引用本文的文献

1
Targeting EGFR/IGF-IR Functional Crosstalk in 2D and 3D Triple-Negative Breast Cancer Models to Evaluate Tumor Progression.在二维和三维三阴性乳腺癌模型中靶向表皮生长因子受体/胰岛素样生长因子-1受体功能串扰以评估肿瘤进展
Int J Mol Sci. 2025 Sep 5;26(17):8665. doi: 10.3390/ijms26178665.
2
Bridging the gap: the role of 3D cell cultures in mimicking tumor microenvironment for enhanced drug testing accuracy.弥合差距:3D细胞培养在模拟肿瘤微环境以提高药物测试准确性方面的作用。
Front Bioeng Biotechnol. 2025 Aug 12;13:1498141. doi: 10.3389/fbioe.2025.1498141. eCollection 2025.
3
Ex-Vivo Drug-Sensitivity Testing to Predict Clinical Response in Non-Small Cell Lung Cancer and Pleural Mesothelioma: A Systematic Review and Narrative Synthesis.
体外药敏试验预测非小细胞肺癌和胸膜间皮瘤的临床反应:一项系统评价和叙述性综合分析
Cancers (Basel). 2025 Mar 14;17(6):986. doi: 10.3390/cancers17060986.
4
3D cell culture models in research: applications to lung cancer pharmacology.研究中的3D细胞培养模型:在肺癌药理学中的应用
Front Pharmacol. 2024 Sep 23;15:1438067. doi: 10.3389/fphar.2024.1438067. eCollection 2024.
5
Caspase-9 suppresses metastatic behavior of MDA-MB-231 cells in an adaptive organoid model.Caspase-9 抑制 MDA-MB-231 细胞在适应性类器官模型中的转移行为。
Sci Rep. 2024 Jul 2;14(1):15116. doi: 10.1038/s41598-024-65711-z.
6
The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients.在3D培养平台上进行的药物疗效测试可为卵巢癌患者确定有效的药物。
NPJ Precis Oncol. 2023 Oct 31;7(1):111. doi: 10.1038/s41698-023-00463-z.
7
Tumor Organoid and Spheroid Models for Cervical Cancer.宫颈癌的肿瘤类器官和球体模型
Cancers (Basel). 2023 Apr 27;15(9):2518. doi: 10.3390/cancers15092518.